• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Stevanato Group, Bexson expand partnership for wearable drug delivery device

April 29, 2022 By Sean Whooley

Stevanato Group SG EZ be Pod®
[Image from Stevanato Group]
Stevanato Group and Bexson Biomedical announced today that they agreed to expand their drug delivery collaboration.

Under the agreement, Bexson has access to the use of a customized version of Stevanato’s SG EZ-be Pod wearable delivery system so it can develop new therapeutics for treating an array of mental health conditions, including treatment-resistant depression and post-traumatic stress disorder (PTSD).

The companies have collaborated since 2020 to optimize the SG EZ-be Pod for treating chronic and acute pain disorders. In November 2021, the companies received pre-investigational new drug guidance from the FDA for a ketamine compound therapy delivered with the system.

Stevanato designed the device as a small, wearable infusion device capable of being programmed for a range of medications and delivery profiles, including at-home delivery.

In a news release, the companies said they hope to use the combination of their technologies to provide the dosing control advantages of intravenous medication delivery without the procedural burden and high costs. They also aim to permit real-time dose attunement in an office setting with the approach.

“We extend our collaboration with Bexson to better suit the needs of patients from different therapeutic areas by developing the modularity of our award-winning SG EZ-be Pod. The extension of our wearable device to a wider range of therapeutic areas may help provide effective and comfortable treatments to patients suffering from mental illness or chronic pain that impacts the quality of their lives,” Stevanato Chief Business Officer Mauro Stocchi said in the release. “The patient-centric SG EZ-be Pod is intended to give patients more flexibility in the administration of medication outside of clinics and hospitals. The partnership with Bexson responds also to the need for sustainability on part of pharmaceutical and biotechnology companies with the goal to reduce the overall cost per treatment.”

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Pain Management Tagged With: Bexson Biomedical, Stevanato Group

IN CASE YOU MISSED IT

  • FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
  • Medtronic completes Intersect ENT acquisition
  • Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes
  • Here’s what’s next for Insulet after the launch of Omnipod 5, CEO change
  • Senseonics beats The Street in Q1 following Eversense E3 launch

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS